TY - JOUR
T1 - Altered Functionality of Anti-Bacterial Antibodies in Patients with Chronic Hepatitis C Virus Infection
AU - Lamontagne, Anne
AU - Long, Ronald E.
AU - Comunale, Mary Ann
AU - Hafner, Julie
AU - Rodemich-Betesh, Lucy
AU - Wang, Mengjun
AU - Marrero, Jorge
AU - Di Bisceglie, Adrian M.
AU - Block, Timothy
AU - Mehta, Anand
PY - 2013/6/4
Y1 - 2013/6/4
N2 - Background:Using comparative glycoproteomics, we have previously identified a glycoprotein that is altered in both amount and glycosylation as a function of liver cirrhosis. The altered glycoprotein is an agalactosylated (G0) immunoglobulin G molecule (IgG) that recognizes the heterophilic alpha-gal epitope. Since the alpha gal epitope is found on gut enterobacteria, it has been hypothesized that anti-gal antibodies are generated as a result of increased bacterial exposure in patients with liver disease.Methods:The N-linked glycosylation of anti-gal IgG molecules from patients with fibrosis and cirrhosis was determined and the effector function of anti-bacterial antibodies from over 100 patients examined. In addition, markers of microbial exposure were determined.Results:Surprisingly, the subset of agalactosylated anti-gal antibodies described here, was impaired in their ability to mediate complement mediated lysis and inhibited the complement-mediated destruction of common gut bacteria. In an analysis of serum from more than 100 patients with liver disease, we have shown that those with increased levels of this modified anti-gal antibody had increased levels of markers of bacterial exposure.Conclusions:Anti-gal antibodies in patients with liver cirrhosis were reduced in their ability to mediate complement mediated lysis of target cells. As bacterial infection is a major complication in patients with cirrhosis and bacterial products such as LPS are thought to play a major role in the development and progression of liver fibrosis, this finding has many clinical implications in the etiology, prognosis and treatment of liver disease.
AB - Background:Using comparative glycoproteomics, we have previously identified a glycoprotein that is altered in both amount and glycosylation as a function of liver cirrhosis. The altered glycoprotein is an agalactosylated (G0) immunoglobulin G molecule (IgG) that recognizes the heterophilic alpha-gal epitope. Since the alpha gal epitope is found on gut enterobacteria, it has been hypothesized that anti-gal antibodies are generated as a result of increased bacterial exposure in patients with liver disease.Methods:The N-linked glycosylation of anti-gal IgG molecules from patients with fibrosis and cirrhosis was determined and the effector function of anti-bacterial antibodies from over 100 patients examined. In addition, markers of microbial exposure were determined.Results:Surprisingly, the subset of agalactosylated anti-gal antibodies described here, was impaired in their ability to mediate complement mediated lysis and inhibited the complement-mediated destruction of common gut bacteria. In an analysis of serum from more than 100 patients with liver disease, we have shown that those with increased levels of this modified anti-gal antibody had increased levels of markers of bacterial exposure.Conclusions:Anti-gal antibodies in patients with liver cirrhosis were reduced in their ability to mediate complement mediated lysis of target cells. As bacterial infection is a major complication in patients with cirrhosis and bacterial products such as LPS are thought to play a major role in the development and progression of liver fibrosis, this finding has many clinical implications in the etiology, prognosis and treatment of liver disease.
UR - http://www.scopus.com/inward/record.url?scp=84878643958&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84878643958&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0064992
DO - 10.1371/journal.pone.0064992
M3 - Article
C2 - 23750224
AN - SCOPUS:84878643958
SN - 1932-6203
VL - 8
JO - PloS one
JF - PloS one
IS - 6
M1 - e64992
ER -